Zurcher Kantonalbank Zurich Cantonalbank Sells 29,474 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 74.3% in the second quarter, Holdings Channel reports. The institutional investor owned 10,170 shares of the specialty pharmaceutical company’s stock after selling 29,474 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Jazz Pharmaceuticals were worth $1,085,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of Jazz Pharmaceuticals by 0.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock worth $1,937,000 after acquiring an additional 99 shares during the last quarter. ProShare Advisors LLC raised its position in Jazz Pharmaceuticals by 1.4% in the 1st quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after purchasing an additional 105 shares during the period. Ontario Teachers Pension Plan Board lifted its stake in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock worth $3,659,000 after purchasing an additional 108 shares during the last quarter. Pinnacle Associates Ltd. boosted its position in shares of Jazz Pharmaceuticals by 1.1% during the first quarter. Pinnacle Associates Ltd. now owns 10,371 shares of the specialty pharmaceutical company’s stock valued at $1,249,000 after buying an additional 110 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on JAZZ shares. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Piper Sandler decreased their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Finally, The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $173.07.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $109.32 on Wednesday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The company has a 50 day moving average price of $109.69 and a 200-day moving average price of $112.53. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $143.32. The stock has a market capitalization of $6.89 billion, a PE ratio of 22.54, a PEG ratio of 1.45 and a beta of 0.58.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.